✦ LIBER ✦

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer : National Cancer Institute of Canada Clinical Trials Group Study PA.3

✍ Scribed by Gilda da Cunha Santos; Neesha Dhani; Dongsheng Tu; Kayu Chin; Olga Ludkovski; Suzanne Kamel-Reid; Jeremy Squire; Wendy Parulekar; Malcolm J. Moore; Ming Sound Tsao

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 311 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25393

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study of platinum and gemcitab

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer : A Trial of the NCIC Clinical Trials Group

✍ Scott A. Laurie; Lillian L. Siu; Eric Winquist; Andrew Maksymiuk; Erica L. Harne 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 1 views

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati

Gemcitabine, dexamethasone, and cisplati

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma : A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)

✍ Michael Crump; Tara Baetz; Stephen Couban; Andrew Belch; Deborah Marcellus; Kang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Identification of potential prognostic b

Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)

✍ Andrew S. Roberts; Michael J. Campa; Elizabeth B. Gottlin; Chen Jiang; Kouros Ow 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB 👁 1 views

Vorinostat in advanced prostate cancer p

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862) : Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium

✍ Deborah Bradley; Dana Rathkopf; Rodney Dunn; Walter M. Stadler; Glenn Liu; David 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views